Pharmaceutical Companies

Ryan & Maniskas, LLP Announces Investigation of Pharmasset, Inc.

Published in Pharma Law Weekly, December 6th, 2011

2011 DEC 6 -- Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/vrus) is investigating potential claims against the board of directors of Pharmasset, Inc. ("Pharmasset" or the "Company") (NASDAQ: VRUS) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell Pharmasset to Gilead Sciences, Inc. in a transaction valued at approximately $11 billion.

Our investigation concerns possible breaches of fiduciary duty and other violations of law related to the approval of the transaction by Company's board of directors; in particular, whether the Company undertook a fair process to obtain fair consideration for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly

Source: Pharma Law Weekly (2011-12-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry